Europska Unija - hrvatski - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - ibedenon - optika atrofija, nasljedna, leber - drugi психостимуляторы i nootropics, psychoanaleptics, - raxone je indiciran za liječenje oštećenja vida kod adolescentnih i odraslih bolesnika s leber's hereditary optic neuropathy (lhon).

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - гемтузумаб ozogamicin - leukemija, mieloidna, akutna - antineoplastična sredstva - mylotarg indiciran za kombinirano liječenje s daunorubicin (ДНР) i цитарабина (wac) za liječenje bolesnika u dobi od 15 godina i više s ranije neobrađeni, de novo cd33-pozitivnih akutnog миелоидного leukemije (aml), osim od akutne leukemije promijelocitna (опл).

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - apalutamide - prostatske neoplazme - endokrinska terapija - erleada drugačije:kod odraslih muškaraca u liječenju ne metastatic кастраци-uporan je rak prostate (nmcrpc), koje imaju visok rizik za razvoj bolesti метастатической. kod odraslih muškaraca u liječenju метастатического hormonski-senzitivni rak prostate (mhspc) u kombinaciji s terapijom oduzimanja андрогена (adt).

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukemija, mieloidna, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - eslicarbazepinum - tableta - 200 mg - urbroj: jedna tableta sadrži 200 mg eslikarbazepinacetata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

accord healthcare polska sp. z o.o., ul. tasmowa 7, mazowieckie, varšava, poljska - eslicarbazepinum - tableta - 800 mg - urbroj: jedna tableta sadrži 800 mg eslikarbazepinacetata

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multipla skleroza, Рецидивно-Ремиттирующее - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipli mijelom - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - ostali dermatološki pripravci - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.